Literature DB >> 8907062

Mixed cryoglobulinemia secondary to hepatitis C virus infection.

V Agnello1, P L Romain.   

Abstract

Mixed cryoglobulinemia is a systemic vasculitis with clinical manifestations ranging from the characteristic benign-appearing syndrome of palpable purpura, arthrologies, and fatigue to severe vasculitis involving vital organs. A strong association of the disease with hepatitis C virus infection and the demonstration of the specific concentration of the virus in the cryoglobulins have implicated hepatitis C virus in the etiopathogenesis of the disease. The increase in illicit intravenous drug use in the past 30 years seems to have raised the occurrence in the United States of this once uncommon disease and changed the demographics: there seem to be more male intravenous drug users in their forties with the disease than women without risk factors for hepatitis C virus infection in their fifties and sixties. Pathogenesis, therapy, and the hypothesis on the etiologic role of hepatitis C virus are reviewed, and the implications of recent studies and new concepts for treatment of this often benign-appearing but deceptive and potentially life-threatening disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907062     DOI: 10.1016/s0889-857x(05)70259-3

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  3 in total

1.  Systemic vasculitis: epidemiology, classification and environmental factors.

Authors:  D G Scott; R A Watts
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

2.  Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection.

Authors:  Y H Lee; J D Ji; J E Yeon; K S Byun; C H Lee; G G Song
Journal:  Ann Rheum Dis       Date:  1998-12       Impact factor: 19.103

Review 3.  The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.

Authors:  V Agnello
Journal:  Springer Semin Immunopathol       Date:  1997
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.